Stocks/TSX-V/XRTX

XORTX Therapeutics Inc (XRTX : TSX-V)

Common Stock

$2.95

CAD

+0.07 (2.43%)

Last updated: 2026-07-14

Get XRTX alerts:

XRTX

XORTX Therapeutics Inc

Source:WealthAwesomeWealthAwesome
โ†“ $0.74 (-20.05%)
30 day period
$2.76$3.27$3.78Apr 28May 28Jul 14

Performance

1 Day

+0.00%

1 Week

+0.00%

1 Month

+0.68%

YTD

-26.25%

Key Statistics

Market Cap

$5.11M

52W High

$9.85

52W Low

$2.42

P/E Ratio

-

50 Day MA

$3.03

200 Day MA

$3.59

Beta

0.17

Dividend Yield

-

Technical Indicators

Price vs 50-Day SMA

โ†“Below 50 SMA

Price vs 200-Day SMA

โ†“Below 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
7/14/2026$2.95$2.95$2.95$2.95$2.95503
7/8/2026$2.93$2.93$2.88$2.88$2.88700
7/3/2026$2.92$2.92$2.92$2.92$2.920
7/2/2026$2.95$2.95$2.92$2.92$2.92400
6/30/2026$3.20$3.20$3.20$3.20$3.201,300
6/23/2026$2.93$2.93$2.93$2.93$2.93301
6/17/2026$3.05$3.05$3.03$3.03$3.031,806
6/16/2026$3.00$3.00$3.00$3.00$3.00308
6/15/2026$3.00$3.00$2.93$3.00$3.002,825
6/10/2026$3.20$3.20$3.20$3.20$3.201,100

Analyst Price Targets

Based on analyst covering XRTX

๐Ÿ“ˆ

Wall Street analysts forecast XRTX stock price to rise 2645.8% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$81.00

+2645.8% Upside

Current Price

C$2.95

Last close

Analyst ratings and price targets are updated periodically. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on XRTX's historical volatility

HistoricalForecast68%95%
C$0.69C$3.34C$5.98C$8.62C$11.27C$13.91TodayDec 15Mar 30Jul 14Aug 26Oct 9Nov 21

30-Day Vol

123.0%

Annualized

90-Day Vol

128.8%

Annualized

Trend (90d)

+14.5%

Annualized drift

90d Mean

C$3.11

Expected price

HorizonExpected68% Range (1ฯƒ)
30 trading daysC$3.00C$1.96 โ€“ C$4.59
60 trading daysC$3.05C$1.68 โ€“ C$5.56
90 trading daysC$3.11C$1.49 โ€“ C$6.48

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯƒ, 95% band = ยฑ2ฯƒ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About XORTX Therapeutics Inc

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Financials

Revenue (TTM)
$0
EBITDA
$-2.42M
Profit Margin
0.00%
ROE (TTM)
-137.44%
EPS (Diluted)
-3.46
Book Value
1.30

Classification

Sector
Health Care
Industry
Biotechnology
Group
Pharmaceuticals, Biotechnology & Life Sciences

๐Ÿ”„ Recent Splits

1-for-5

Apr 6, 2026

Reverse

1-for-9

Nov 14, 2023

Reverse

Advertisement

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Common Questions About XRTX

Advertisement